Primecap Management CO Adverum Biotechnologies, Inc. Transaction History

Primecap Management CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $2.33 Million - $5.56 Million	-455,000 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$5.24 - $15.89 $3.29 Million - $9.96 Million	-627,000 Reduced 57.95%	455,000 $2.48 Million
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $153,000 - $356,700	30,000 Added 2.85%	1,082,000 $12.9 Million
Q4 2018 Feb 12, 2019	BUY	$2.87 - $5.92 $622,503 - $1.28 Million	216,900 Added 25.97%	1,052,000 $3.31 Million
Q3 2018 Nov 13, 2018	BUY	$4.5 - $7.6 $1.49 Million - $2.52 Million	331,700 Added 65.89%	835,100 $5.05 Million
Q4 2017 Feb 13, 2018	BUY	$2.85 - $3.95 $53,865 - $74,655	18,900 Added 3.9%	503,400 $1.76 Million
Q3 2017 Nov 13, 2017	BUY	$2.45 - $3.65 $1.19 Million - $1.77 Million	484,500	484,500 $1.77 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $611M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

Stay updated on Primecap Management CO with notifications on news.